Nicole Malliotakis

So maybe 18% should be more of what we're looking at for one year to kind of bring it in par.

But I think this is going to be a real big discussion on Capitol Hill because I can tell you, I was a member of the Main Street Caucus, which is more center-right members of our conference.

A lot of them have expressed...

concerns about this in our last meeting, which took place on Monday.

And so I do believe that this is really, really going to be something that he's going to get a lot of opposition to on the Hill.

Yeah, look, I think that the president just a little while ago came out with his great health care plan, and we're currently reviewing that.

It does hit on a lot of the points.

I mean, I think one of the big issues where we see some opportunity is pharmaceuticals, right?

He's proposed his most favored nation.

He wants Americans to pay the same price that many other countries are paying.

Why are we subsidizing the research and on top of it paying the highest prices?

So he has a point with that, but

I think the bigger issue is PBM reform, if we want to rein in those PBMs that are those middlemen between the insurance companies and the pharmacies.

In some cases, there's vertical integration where the insurance company is the PBM and the pharmacy.

That is, I think, a real problem because we're seeing them put small mom-and-pop pharmacies out of business.

They're dictating what their competitors are making.

And they have no transparency in terms of what's going on in the middle in between phase and how much they're profiting.

So in fact, our committee next week, Ways and Means, is going to be having these health insurance executives that do also own these PBMs.

come before us.

And the questions are, it's going to be interesting, especially when we, when we asked them, you know, about the 230% increase in profits, uh, and, and the premiums increasing at the same time, despite those taxpayer subsidies.